Alloreactive killer cells: Hindrance and help for haematopoietic transplants

被引:127
作者
Parham, P [1 ]
McQueen, KL
机构
[1] Stanford Univ, Dept Biol Struct, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nri999
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Haematopoietic-cell transplantation is a treatment for leukaemia and lymphoma. To reduce the incidence of graft-versus-host disease (GVHD) caused by transplanted T cells, donors and recipients are HLA matched. For patients for whom a matched donor is not available, one option is transplantation from an HLA-mismatched relative who shares one HLA haplotype. This procedure is distinguished by the use of a stronger conditioning regimen for the patient and of a T-cell-depleted graft containing numerous stem cells. After transplantation, natural killer cells are prevalent, and they can include alloreactive cells that kill tumour cells and prevent GVHD. The alloreactions seem to be determined by the mismatched HLA class I ligands and their killer-cell immunoglobulin-like receptors.
引用
收藏
页码:108 / 122
页数:15
相关论文
共 149 条
[1]   SUCCESSFUL ENGRAFTMENT OF T-CELL-DEPLETED HAPLOIDENTICAL 3-LOCI INCOMPATIBLE TRANSPLANTS IN LEUKEMIA PATIENTS BY ADDITION OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR-MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS TO BONE-MARROW INOCULUM [J].
AVERSA, F ;
TABILIO, A ;
TERENZI, A ;
VELARDI, A ;
FALZETTI, F ;
GIANNONI, C ;
IACUCCI, R ;
ZEI, T ;
MARTELLI, MP ;
GAMBELUNGHE, C ;
ROSSETTI, M ;
CAPUTO, P ;
LATINI, P ;
ARISTEI, C ;
RAYMONDI, C ;
REISNER, Y ;
MARTELLI, MF .
BLOOD, 1994, 84 (11) :3948-3955
[2]   Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype [J].
Aversa, F ;
Tabilio, A ;
Velardi, A ;
Cunningham, I ;
Terenzi, A ;
Falzetti, F ;
Ruggeri, L ;
Barbabietola, G ;
Aristei, C ;
Latini, P ;
Reisner, Y ;
Martelli, MF .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (17) :1186-1193
[3]   Umbilical cord blood transplantation: current state of the art [J].
Barker, JN ;
Wagner, JE .
CURRENT OPINION IN ONCOLOGY, 2002, 14 (02) :160-164
[4]   Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation [J].
Baron, F ;
Beguin, Y .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (07) :351-359
[5]   Graft-versus-leukaemia: Understanding and using the alloimmune response to treat haematological malignancies [J].
Barrett, AJ ;
Malkovska, V .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 (04) :754-761
[6]   BIOLOGY AND GENETICS OF HYBRID RESISTANCE [J].
BENNETT, M .
ADVANCES IN IMMUNOLOGY, 1987, 41 :333-445
[7]  
Bensinger W I, 2001, Rev Clin Exp Hematol, V5, P67, DOI 10.1046/j.1468-0734.2001.00033.x
[8]   Blood or marrow? [J].
Bensinger, WI ;
Deeg, HJ .
LANCET, 2000, 355 (9211) :1199-1200
[9]   A review of autologous hematopoietic cell transplantation [J].
Blume, KG ;
Thomas, ED .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2000, 6 (01) :1-12
[10]   Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis [J].
Borrego, F ;
Ulbrecht, M ;
Weiss, EH ;
Coligan, JE ;
Brooks, AG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (05) :813-818